Dianna K Hughbanks-Wheaton1, David G Birch1, Gary E Fish2, Rand Spencer2, N Shirlene Pearson3, Alison Takacs4, Dennis R Hoffman1. 1. Retina Foundation of the Southwest, Dallas, Texas, United States Department of Ophthalmology, UT Southwestern Medical Center, Dallas, Texas, United States. 2. Texas Retina Associates, Dallas, Texas, United States. 3. Pearson Statistical Consulting & Expert Testimony, Richardson, Texas, United States. 4. Retina Foundation of the Southwest, Dallas, Texas, United States.
Abstract
PURPOSE:Docosahexaenoic acid (DHA) continues to be evaluated and recommended as treatment and prophylaxis for various diseases. We recently assessed efficacy of high-dose DHA supplementation to slow vision loss in patients with X-linked retinitis pigmentosa (XLRP) in a randomized clinical trial. Because DHA is a highly unsaturated fatty acid, it could serve as a target for free-radical induced oxidation, resulting in increased oxidative stress. Biosafety was monitored during the 4-year trial to determine whether DHA supplementation was associated with identifiable risks. METHODS:Males (n = 78; 7-31 years) meeting entry criteria were enrolled. The modified intent-to-treat cohort (DHA = 33; placebo = 27) adhered to the protocol ≥ 1 year. Participants were randomized to an oral dose of 30 mg/kg/d DHA or placebo plus a daily multivitamin. Comprehensive metabolic analyses were assessed for group differences. Treatment-emergent adverse events including blood chemistry metabolites were recorded. RESULTS: By year 4, supplementation elevated plasma and red blood cell-DHA 4.4- and 3.6-fold, respectively, compared with the placebo group (P < 0.00001). Over the trial duration, no significant differences between DHA and placebo groups were found for vitamin A, vitamin E, platelet aggregation, antioxidant activity, lipoprotein cholesterol, or oxidized LDL levels (all P > 0.14). Adverse events were transient and not considered severe (e.g., gastrointestinal [GI] irritability, blood chemistry alterations). One participant was unable to tolerate persistent GI discomfort. CONCLUSIONS: Long-term, high-dose DHA supplementation to patients with XLRP was associated with limited safety risks in this 4-year trial. Nevertheless, GI symptoms should be monitored in all patients taking high dose DHA especially those with personal or family history of GI disturbances. (ClinicalTrials.gov number, NCT00100230.). Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
RCT Entities:
PURPOSE:Docosahexaenoic acid (DHA) continues to be evaluated and recommended as treatment and prophylaxis for various diseases. We recently assessed efficacy of high-dose DHA supplementation to slow vision loss in patients with X-linked retinitis pigmentosa (XLRP) in a randomized clinical trial. Because DHA is a highly unsaturated fatty acid, it could serve as a target for free-radical induced oxidation, resulting in increased oxidative stress. Biosafety was monitored during the 4-year trial to determine whether DHA supplementation was associated with identifiable risks. METHODS: Males (n = 78; 7-31 years) meeting entry criteria were enrolled. The modified intent-to-treat cohort (DHA = 33; placebo = 27) adhered to the protocol ≥ 1 year. Participants were randomized to an oral dose of 30 mg/kg/d DHA or placebo plus a daily multivitamin. Comprehensive metabolic analyses were assessed for group differences. Treatment-emergent adverse events including blood chemistry metabolites were recorded. RESULTS: By year 4, supplementation elevated plasma and red blood cell-DHA 4.4- and 3.6-fold, respectively, compared with the placebo group (P < 0.00001). Over the trial duration, no significant differences between DHA and placebo groups were found for vitamin A, vitamin E, platelet aggregation, antioxidant activity, lipoprotein cholesterol, or oxidized LDL levels (all P > 0.14). Adverse events were transient and not considered severe (e.g., gastrointestinal [GI] irritability, blood chemistry alterations). One participant was unable to tolerate persistent GI discomfort. CONCLUSIONS: Long-term, high-dose DHA supplementation to patients with XLRP was associated with limited safety risks in this 4-year trial. Nevertheless, GI symptoms should be monitored in all patients taking high dose DHA especially those with personal or family history of GI disturbances. (ClinicalTrials.gov number, NCT00100230.). Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Dennis R Hoffman; Richard C Theuer; Yolanda S Castañeda; Dianna H Wheaton; Rain G Bosworth; Anna R O'Connor; Sarah E Morale; Lindsey E Wiedemann; Eileen E Birch Journal: J Nutr Date: 2004-09 Impact factor: 4.798
Authors: Dennis R Hoffman; Kirsten G Locke; Dianna H Wheaton; Gary E Fish; Rand Spencer; David G Birch Journal: Am J Ophthalmol Date: 2004-04 Impact factor: 5.258
Authors: J Thomas Brenna; Behzad Varamini; Robert G Jensen; Deborah A Diersen-Schade; Julia A Boettcher; Linda M Arterburn Journal: Am J Clin Nutr Date: 2007-06 Impact factor: 7.045
Authors: Dennis R Hoffman; Dianna K Hughbanks-Wheaton; Rand Spencer; Gary E Fish; N Shirlene Pearson; Yi-Zhong Wang; Martin Klein; Alison Takacs; Kirsten G Locke; David G Birch Journal: Invest Ophthalmol Vis Sci Date: 2015-10 Impact factor: 4.799
Authors: N Brito-García; T Del Pino-Sedeño; M M Trujillo-Martín; R M Coco; E Rodríguez de la Rúa; I Del Cura-González; P Serrano-Aguilar Journal: Eye (Lond) Date: 2016-12-09 Impact factor: 3.775
Authors: Dominique Turck; Jacqueline Castenmiller; Stefaan De Henauw; Karen Ildico Hirsch-Ernst; John Kearney; Alexandre Maciuk; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Carmen Pelaez; Kristina Pentieva; Alfonso Siani; Frank Thies; Sophia Tsabouri; Marco Vinceti; Francesco Cubadda; Thomas Frenzel; Marina Heinonen; Rosangela Marchelli; Monika Neuhäuser-Berthold; Morten Poulsen; Miguel Prieto Maradona; Josef Rudolf Schlatter; Henk van Loveren; Emanuela Turla; Helle Katrine Knutsen Journal: EFSA J Date: 2021-01-19